IPP Bureau
NATHEALTH Home Care Forum launches white paper on healthcare delivery
By IPP Bureau - January 06, 2022
10 implementation focused initiatives recommended to accelerate policy reforms, standardization of home care delivery services, and improve accessibility and affordability of care in tier II and tier III geographies
ENTOD Pharmaceuticals set to launch Molentod
By IPP Bureau - January 06, 2022
It is the generic version of molnupiravir
U.S. FDA grants approval for Alembic’s Parkinson’s drug
By IPP Bureau - January 06, 2022
Entacapone tablets USP, 200 mg have an estimated market size of US$ 10.5 million for twelve months ending September 2021, according to IQVIA
Dr. K.V.S Ram Rao is the new JMD & CEO of Granules India
By IPP Bureau - January 05, 2022
He has over 29 years of experience in the field of manufacturing, R&D, business and customer service management
Biogen exercises option with Ionis for spinal muscular atrophy
By IPP Bureau - January 05, 2022
Biogen paid Ionis a US $ 60 million one-time upfront payment
Jemincare confirms its antibody effective against Omicron
By IPP Bureau - January 05, 2022
The latest research results indicated that JMB2002 had high binding activity to the Omicron variant and showed potent Omicron pseudovirus neutralization function
Bharat Biotech's intranasal vaccine Phase 3 trials gets approval
By IPP Bureau - January 05, 2022
It has also been granted permission to conduct trials for booster dose
Tata Medical develops OmiSure to detect Omicron
By IPP Bureau - January 05, 2022
The test kit is compatible with all standard Real-Time PCR machines with a test run time of 85 minutes. The result turnaround time, including sample collection and RNA extraction, is 130 minutes
Dassault Systèmes to showcase the Virtual Twin Experience of the human body at CES 2022
By IPP Bureau - January 04, 2022
The virtual world makes it possible to visualize, test, understand and predict what cannot be seen, before a patient is treated
Ayush Minister lays foundation stone for Heartfulness International Yoga academy
By IPP Bureau - January 04, 2022
The Academy endeavours to reach all levels of the society in creating programs that are accessible to one and all with training for Health Volunteers, Asha, Angavadi, school-teachers and students as part of life-skill development
Transcat acquires Tangent Labs for US $ 9 million
By IPP Bureau - January 04, 2022
Tangent offers ISO/IEC 17025-accredited calibrations and has labs located in both Indianapolis and Huntsville, Alabama
USFDA grants ILiAD Biotechnologies Fast Track Designation for pertussis vaccine
By IPP Bureau - January 04, 2022
BPZE1 is the most advanced next-generation pertussis vaccine currently in clinical development
Amyris and ImmunityBio JV for next gen Covid-19 RNA vaccine
By IPP Bureau - January 04, 2022
Upon completion of successful human trials and regulatory approval, the joint venture's goal is to start delivering the second-generation vaccine in 2022 as soon as is practically possible
Alembic receives USFDA approval for Doxycycline Hyclate
By IPP Bureau - January 04, 2022
Doxycycline Hyclate Delayed Release tablets should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria
Kyverna Therapeutics announces licence agreement with NIH
By IPP Bureau - January 04, 2022
This next-generation CAR T construct was designed to improve the tolerability profile of conventional CD19 CAR Ts and developed in the laboratory of James N. Kochenderfer, M.D., at the National Cancer Institute, part of the NIH, the same laboratory that discovered axicabtagene ciloleucel
